GeNO has received clearance from the U.S. Food and Drug Administration (FDA) to market its inhaled nitric oxide (NO) delivery system, GeNOsyl™ MV-1000; the first of a series of ventilator products being developed.
The GeNOsyl™ MV-1000 delivery system incorporates four components: the primary delivery system, a backup system, the NO gas analyzer, and the nitrogen dioxide (NO2) gas analyzer. The GeNOsyl™ MV-1000 injects a constant flow of NO gas into the inspiratory limb of the ventilator circuit to deliver a constant concentration of NO to the patient. It provides continuous integrated monitoring of inspired oxygen, NO and NO2 concentrations, and a comprehensive alarm system. Prior to reaching the patient, the gas passes through the GeNO cartridge, which serves two functions: 1) as a mixing chamber, and 2) to chemically convert to NO any NO2 which may be present, so as to deliver NO with extremely low levels of the NO2 impurity.